[A23-23] Dupilumab (eosinophilic oesophagitis) – Benefit assessment according to §35a Social Code Book V
Last updated 03.07.2023
Project no.:
A23-23
Commission:
Commission awarded on 30.03.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Indication:
Eosinophilic oesophagitis (EoE)
Result of dossier assessment:
- Adults with EoE who are still candidates for treatment with budesonide because they have not yet received budesonide: added benefit not proven
- Adults and adolescents with EoE, 12 years and older, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.